Join to access to all OVN content. Join Now

Results for 'payer'

...
OVN Avatar Melissa H. Roberts & Gary T. Ferguson
Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions

Jun 18th • 6 mins read

...
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Jan 7th • 8 mins read

...
OVN Avatar Consolacion Molto, Ariadna Tibau, Aida Bujosa, Jose Carlos Tapia, Abhenil Mittal, Faris Tamimi & Eitan Amir
Association between control group therapy and magnitude of clinical benefit of cancer drugs

Dec 9th • 20 mins read

...
Partner Avatar Envision Pharma Group
Medical affairs: The power behind redefining commercialization

Aug 2nd • 3 mins read

...
OVN Avatar Garth W. Strohbehn, MD, MPhil, Allen S. Lichter, MD and Mark J. Ratain, MD
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Feb 13th • 5 mins read

...
OVN Avatar Diana Brixner, PhD, RPh [email protected], Joseph Biskupiak, PhD, MBA, Gary Oderda, PharmD, MPH, Douglas Burgoyne, PharmD, FAMCP, Daniel C Malone, RPh, PhD, FAMCP, Bhakti Arondekar, PhD, MBA, and Alexander Niyazov, PharmD, RPh, MPH
Payer perceptions of the use of real-world evidence in oncology-based decision making

Aug 1st • 12 mins read

...
OVN Avatar Meena N Murugappan, PharmD, MPH, PhD(c), Bellinda L King-Kallimanis, PhD, Gregory H Reaman, MD, Vishal Bhatnagar, MD, Erica G Horodniceanu, MPH, Najat Bouchkouj, MD, Paul G Kluetz, MD
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective

Apr 30th • 12 mins read

...
OVN Avatar Carina Dolan, PharmD, BCOP
Opportunities and challenges in biosimilar uptake in oncology

Jun 26th • 7 mins read

...
OVN Avatar Nicole M. Kuderer and Gary H. Lyman
Evolving Landscape of US Food and Drug Administration Drug Approval in the Era of Precision Oncology: Finding the Right Balance Between Access and Safety

Jun 20th • 3 mins read

...
Partner Avatar Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access

Aug 22nd • 5 mins read